GlassScriptPhysician profile
Berneet Kaur
NPI 1477729002
$26,513.19
in general payments reported to CMS, 2019-2025
45 companies · $5,106 in 2025
The $5,106 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $112 · 2021: $230 · 2022: $102 · 2023: $13K · 2024: $7,246 · 2025: $5,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $4,743 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,680 · Food and Beverage: $4,368 · Travel and Lodging: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,705.00 |
| Consulting Fee | $4,742.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,680.00 |
| Food and Beverage | $4,367.66 |
| Travel and Lodging | $1,224.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22,610.28 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $545.23 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $453.41 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Otsuka America Pharmaceutical, INC. | $452.18 | 2023-2025 | Rexulti |
| Abbvie INC. | $267.05 | 2023-2025 | |
| Neurelis, INC. | $176.34 | 2023-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $148.57 | 2023-2025 | |
| Lundbeck LLC | $140.63 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $118.42 | 2021-2024 | Spinraza, Qalsody, Skyclarys |
| Sunovion Pharmaceuticals INC. | $110.51 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $103.51 | 2022-2024 | Amvuttra |
| Acadia Pharmaceuticals INC | $102.14 | 2019-2025 | Nuplazid |
| Genentech USA, INC. | $92.38 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $88.60 | 2020-2021 | |
| Argenx US, INC. | $81.07 | 2023-2024 | Vyvgart Hytrulo |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $74.32 | 2022-2024 | |
| Acorda Therapeutics, INC | $64.62 | 2019-2024 | Inbrija |
| Sumitomo Pharma America, INC. | $63.98 | 2023-2024 | Aptiom |
| Emd Serono, INC. | $61.71 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $58.05 | 2024-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $49.64 | 2024 | Crexont, Rytary |
| Axsome Therapeutics, INC. | $47.61 | 2025 | Symbravo, Sunosi |
| Sk Life Science, INC. | $47.19 | 2023-2024 | |
| Ucb, INC. | $44.80 | 2023-2024 | Rystiggo |
| Alexion Pharmaceuticals, INC. | $43.10 | 2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $39.74 | 2023-2025 | Wainua |
| Inspire Medical Systems, INC. | $39.39 | 2025 | Inspire |
| Revance Therapeutics, INC. | $36.40 | 2024 | Daxxify |
| Kyowa Kirin, INC. | $36.03 | 2019 | |
| Pfizer INC. | $32.78 | 2023 | |
| Merz Pharmaceuticals, LLC | $28.99 | 2023 | Xeomin |
| Itf Therapeutics LLC | $27.64 | 2025 | |
| Amylyx Pharmaceuticals, INC. | $23.82 | 2023 | Relyvrio |
| Genzyme Corporation | $23.31 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.68 | 2024 | Keveyis |
| Celgene Corporation | $22.18 | 2023 | Zeposia |
| Nevro Corp. | $21.32 | 2024 | Senza |
| Csl Behring | $19.19 | 2024 | Hizentra |
| Merz North America, INC. | $18.89 | 2019 | |
| Insightec,INC | $17.48 | 2025 | Exablate |
| Arbor Pharmaceuticals, INC. | $15.15 | 2020 | |
| Amgen INC. | $14.51 | 2019 | |
| Promius Pharma LLC | $12.76 | 2019 | |
| Allergan, INC. | $11.16 | 2020 | |
| Corium, LLC | $4.43 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berneet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.